https://www.selleckchem.com/products/LBH-589.html
Despite use of 23-valent pneumococcal polysaccharide vaccine (PPV23) in England, disease burden among at-risk adults remains high. We evaluated the public health and budgetary impact of 20-valent pneumococcal conjugate vaccine (PCV2 compared to the current adult pneumococcal vaccination program. Five-year outcomes and costs of invasive pneumococcal disease (IPD) and community-acquired pneumonia (CAP) among adults aged 65-99years and adults aged 18-64years with underlying conditions in England were projected using a deterministic cohor
Like
Comment
Share
